Trials / Completed
CompletedNCT00397722
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW876008 | |
| DRUG | paroxetine |
Timeline
- Start date
- 2006-11-09
- Primary completion
- 2007-09-05
- Completion
- 2007-09-05
- First posted
- 2006-11-09
- Last updated
- 2017-07-11
Locations
33 sites across 7 countries: United States, Canada, Finland, Germany, Norway, South Africa, Sweden
Source: ClinicalTrials.gov record NCT00397722. Inclusion in this directory is not an endorsement.